medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2013, Número 03-04

<< Anterior Siguiente >>

Medicina & Laboratorio 2013; 19 (03-04)


Síndrome de resistencia a las hormonas tiroideas: reporte de un caso

Gutiérrez RJ, Montoya EJF

Idioma: Español
Referencias bibliográficas: 57
Paginas: 161-171
Archivo PDF: 304.08 Kb.


RESUMEN

El síndrome de resistencia a las hormonas tiroideas es una entidad poco frecuente que se caracteriza por concentraciones elevadas de tiroxina libre y triyodotironina libre, tirotropina normal o ligeramente elevada, en ausencia de cualquier otra enfermedad, medicación o antagonista que causen alteraciones sobre la función tiroidea. Se reporta un caso de una mujer a quien se le realizó diagnóstico de resistencia a las hormonas tiroideas con base en los antecedentes personales, las manifestaciones clínicas y los hallazgos de laboratorio; además, se realiza una revisión de la literatura, con énfasis en el diagnóstico y el tratamiento de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. López JM, Jiménez M, Campino C. Resistencia generalizada a hormonas tiroideas de carácter familiar. Rev Méd Chile 2004; 132: 1096-1099.

  2. Olateju TO, Vanderpump MP. Thyroid hormone resistance. Ann Clin Biochem 2006; 43: 431-440.

  3. Refetoff S, DeWind LT, DeGroot LJ. Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab 1967; 27: 279-294.

  4. Weiss RE, Refetoff S. Resistance to thyroid hormone. Rev Endocr Metab Disord 2000; 1: 97-108.

  5. Beck-Peccoz P, Chatterjee VK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid 1994; 4: 225-232.

  6. Beck-Peccoz P, Persani L, Calebiro D, Bonomi M, Mannavola D, Campi I. Syndromes of hormone resistance in the hypothalamic-pituitary-thyroid axis. Best Pract Res Clin Endocrinol Metab 2006; 20: 529-546.

  7. Kim TJ, Travers S. Case report: thyroid hormone resistance and its therapeutic challenges. Curr Opin Pediatr 2008; 20: 490-493.

  8. Parikh S, Ando S, Schneider A, Skarulis MC, Sarlis NJ, Yen PM. Resistance to thyroid hormone in a patient without thyroid hormone receptor mutations. Thyroid 2002; 12: 81-86.

  9. Refetoff S. The syndrome of resistance to thyroid stimulating hormone. J Chin Med Assoc 2003; 66: 441-452.

  10. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993; 14: 348-399.

  11. Refetoff S. Resistance to thyrotropin. J Endocrinol Invest 2003; 26: 770-779.

  12. Takeda K, Sakurai A, DeGroot LJ, Refetoff S. Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-beta gene. J Clin Endocrinol Metab 1992; 74: 49-55.

  13. Taniyama M, Ishikawa N, Momotani N, Ito K, Ban Y. Toxic multinodular goitre in a patient with generalized resistance to thyroid hormone who harbours the R429Q mutation in the thyroid hormone receptor beta gene. Clin Endocrinol (Oxf) 2001; 54: 121-124.

  14. Weiss RE, Hayashi Y, Nagaya T, Petty KJ, Murata Y, Tunca H, et al. Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptor alpha or beta genes may be due to a defective cofactor. J Clin Endocrinol Metab 1996; 81: 4196-4203.

  15. Fukata S, Brent GA, Sugawara M. Resistance to thyroid hormone in Hashimoto’s thyroiditis. N Engl J Med 2005; 352: 517-518.

  16. Sato H, Sakai H. A family showing resistance to thyroid hormone associated with chronic thyroiditis and its clinical features: A case report. Endocr J 2006; 53: 421-425.

  17. Ogawa K, Yoshida M, Hayashi Y, Murata Y, Miyata M, Oiso Y. A rare case of resistance to thyroid hormone coexisting with Graves’ disease. Endocrine 2011; 40: 318-319.

  18. Sato H. Clinical features of primary hyperthyroidism caused by Graves’ disease admixed with resistance to thyroid hormone (P453T). Endocr J 2010; 57: 687-692.

  19. Sivakumar T, Chaidarun S. Resistance to thyroid hormone in a patient with coexisting Graves’ disease. Thyroid 2010; 20: 213-216.

  20. Anzai R, Adachi M, Sho N, Muroya K, Asakura Y, Onigata K. Long-term 3,5,3’-triiodothyroacetic acid therapy in a child with hyperthyroidism caused by thyroid hormone resistance: pharmacological study and therapeutic recommendations. Thyroid 2012; 22: 1069-1075.

  21. Safer JD, Cohen RN, Hollenberg AN, Wondisford FE. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. J Biol Chem 1998; 273: 30175-30182.

  22. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ. A structural role for hormone in the thyroid hormone receptor. Nature 1995; 378: 690- 697.

  23. Collingwood TN, Adams M, Tone Y, Chatterjee VK. Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome. Mol Endocrinol 1994; 8: 1262- 1277.

  24. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998; 280: 1747-1749.

  25. Bayraktaroglu T, Noel J, Alagol F, Colak N, Mukaddes NM, Refetoff S. Thyroid hormone receptor beta gene mutation (P453A) in a family producing resistance to thyroid hormone. Exp Clin Endocrinol Diabetes 2009; 117: 34-37.

  26. Sarkissian G, Dace A, Mesmacque A, Bony-Trifunovic H, Malezet-Desmoulins C, Torresani J, et al. A novel resistance to thyroid hormone associated with a new mutation (T329N) in the thyroid hormone receptor beta gene. Thyroid 1999; 9: 165-171.

  27. Sato H, Koike Y, Honma M, Yagame M, Ito K. Evaluation of thyroid hormone action in a case of generalized resistance to thyroid hormone with chronic thyroiditis: discovery of a novel heterozygous missense mutation (G347A). Endocr J 2007; 54: 727-732.

  28. Furlanetto TW, Kopp P, Peccin S, Gu WX, Jameson JL. A novel mutation (M310L) in the thyroid hormone receptor beta causing resistance to thyroid hormone in a Brazilian kindred and a neonate. Mol Genet Metab 2000; 71: 520-526.

  29. Magalhaes PK, Rodrigues Dare GL, Rodrigues Dos Santos S, Nogueira CR, de Castro M, Zanini Maciel LM. Clinical features and genetic analysis of four Brazilian kindreds with resistance to thyroid hormone. Clin Endocrinol (Oxf) 2007; 67: 748-753.

  30. Matsushita A, Misawa H, Andoh S, Natsume H, Nishiyama K, Sasaki S, et al. Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT. J Endocrinol 2000; 167: 493-503.

  31. Weiss RE, Xu J, Ning G, Pohlenz J, O’Malley BW, Refetoff S. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 1999; 18: 1900-1904.

  32. Kim HK, Kim D, Yoo EH, Lee JI, Jang HW, Tan AH, et al. A case of resistance to thyroid hormone with thyroid cancer. J Korean Med Sci 2010; 25: 1368-1371.

  33. Paragliola RM, Lovicu RM, Locantore P, Senes P, Concolino P, Capoluongo E, et al. Differentiated thyroid cancer in two patients with resistance to thyroid hormone. Thyroid 2011; 21: 793-797.

  34. Alberto G, Novi RF, Scalabrino E, Trombetta A, Seardo MA, Maurino M, et al. Atrial fibrillation and mitral prolapse in a subject affected by Refetoff syndrome. Minerva Cardioangiol 2002; 50: 157-160.

  35. Kahaly GJ, Matthews CH, Mohr-Kahaly S, Richards CA, Chatterjee VK. Cardiac involvement in thyroid hormone resistance. J Clin Endocrinol Metab 2002; 87: 204-212.

  36. Pulcrano M, Palmieri EA, Mannavola D, Ciulla M, Campi I, Covelli D, et al. Impact of resistance to thyroid hormone on the cardiovascular system in adults. J Clin Endocrinol Metab 2009; 94: 2812- 2816.

  37. Dhingra S, Owen PJ, Lazarus JH, Amin P. Resistance to thyroid hormone in pregnancy. Obstet Gynecol 2008; 112: 501-503.

  38. Kane S, Fox R, Close C. Thyroid hormone resistance and pregnancy. BJOG 2003; 110: 633-634.

  39. Kourides IA, Ridgway EC, Weintraub BD, Bigos ST, Gershengorn MC, Maloof F. Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors. J Clin Endocrinol Metab 1977; 45: 534-543.

  40. Beck-Peccoz P, Persani L. Medical management of thyrotropin- secreting pituitary adenomas. Pituitary 2002; 5: 83-88.

  41. Beck-Peccoz P, Persani L. Thyrotropinomas. Endocrinol Metab Clin North Am 2008; 37: 123-134, viii-ix.

  42. Kienitz T, Quinkler M, Strasburger CJ, Ventz M. Longterm management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol 2007; 157: 39-46.

  43. Safer JD, Colan SD, Fraser LM, Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. Thyroid 2001; 11: 281- 291.

  44. Salmela PI, Wide L, Juustila H, Ruokonen A. Effects of thyroid hormones (T4,T3), bromocriptine and Triac on inappropriate TSH hypersecretion. Clin Endocrinol (Oxf) 1988; 28: 497-507.

  45. Dundar B, Bober E, Buyukgebiz A. Successful therapy with L-T4 in a 5 year-old boy with generalized thyroid hormone resistance. J Pediatr Endocrinol Metab 2003; 16: 1051-1056.

  46. Iglesias P, José-Díez J. Posibilidades terapéuticas en la resistencia hipofisaria selectiva a las hormonas tiroideas. Med Clin (Barc) 2008; 130: 345-350.

  47. Weiss RE, Refetoff S. Treatment of resistance to thyroid hormone--primum non nocere. J Clin Endocrinol Metab 1999; 84: 401-404.

  48. Beck-Peccoz P, Medri G, Piscitelli G, Mariotti S, Bertoli A, Barbarino A, et al. Treatment of inappropriate secretion of thyrotropin with somatostatin analog SMS 201-995. Horm Res 1988; 29: 121-123.

  49. Kannan S, Safer JD. Finding the right balance between resistance and sensitivity: a review of the cardiac manifestations of the syndrome of resistance to thyroid hormone and the implications for treatment. Endocr Pract 2012; 18: 252-255.

  50. Dorey F, Strauch G, Gayno JP. Thyrotoxicosis due to pituitary resistance to thyroid hormones. Successful control with D thyroxine: a study in three patients. Clin Endocrinol (Oxf) 1990; 32: 221-228.

  51. Hamon P, Bovier-Lapierre M, Robert M, Peynaud D, Pugeat M, Orgiazzi J. Hyperthyroidism due to selective pituitary resistance to thyroid hormones in a 15-month-old boy: efficacy of D-thyroxine therapy. J Clin Endocrinol Metab 1988; 67: 1089-1093.

  52. Takeda T, Suzuki S, Liu RT, DeGroot LJ. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab 1995; 80: 2033-2040.

  53. Ueda S, Takamatsu J, Fukata S, Tanaka K, Shimizu N, Sakata S, et al. Differences in response of thyrotropin to 3,5,3’-triiodothyronine and 3,5,3’-triiodothyroacetic acid in patients with resistance to thyroid hormone. Thyroid 1996; 6: 563-570.

  54. Darendeliler F, Bas F. Successful therapy with 3,5,3’-triiodothyroacetic acid (TRIAC) in pituitary resistance to thyroid hormone. J Pediatr Endocrinol Metab 1997; 10: 535-538.

  55. Radetti G, Persani L, Molinaro G, Mannavola D, Cortelazzi D, Chatterjee VK, et al. Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid 1997; 7: 775-778.

  56. de Luis DA, Lahera M, Botella JI, Valero MA, Varela C. Eficacia de la quinagolida en el tratamiento de un paciente con resistencia hipofisiaria a hormonas tiroideas. An Med Interna (Madrid) 2001; 18: 259-261.

  57. Dulgeroff AJ, Geffner ME, Koyal SN, Wong M, Hershman JM. Bromocriptine and Triac therapy for hyperthyroidism due to pituitary resistance to thyroid hormone. J Clin Endocrinol Metab 1992; 75: 1071-1075.




2020     |     www.medigraphic.com